Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page gains new user-guidance sections and a renamed Intervention/Treatment area, while also showing that recruitment is closed and noting a page revision to v3.6.0.SummaryDifference0.4%

- Check13 days agoChange DetectedRevision: v3.5.5 was added, replacing Revision: v3.5.4. This reflects a site update rather than any change to the study details or eligibility criteria.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.5.4 now appears on the page, updating the site version label. The previous label Revision: v3.5.3 has been removed.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page’s displayed revision/version label was updated from v3.5.2 to v3.5.3, indicating a platform release rather than a change to the study record content.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.